Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÈòÁã Åιػù¿¡¼­ fluoxetine Åõ¿©¿¡ ÀÇÇÑ Ä§ºÐºñ ¹× muscarinic acetylcholine receptor M3 ¹ßÇö °¨¼Ò

Reduction of salivation and muscarinic acetylcholine receptor M3 expression in the submandibular gland of the rat by chronic fluoxetine administration

´ëÇѱ¸°­ÇغÎÇÐȸÁö 2016³â 37±Ç 1È£ p.27 ~ 35
Á¤º¸Çö, ÀÓÀ¯¼±, ÀÌÈñ¼ö, À¯±â¿¬,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤º¸Çö ( Jung Bo-Hyun ) - °­¸ª¿øÁÖ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­ÇغÎÇб³½Ç
ÀÓÀ¯¼± ( Lim You-Sun ) - °­¸ª¿øÁÖ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­ÇغÎÇб³½Ç
ÀÌÈñ¼ö ( Lee Hee-Su ) - °­¸ª¿øÁÖ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­ÇغÎÇб³½Ç
À¯±â¿¬ ( Yoo Ki-Yeon ) - °­¸ª¿øÁÖ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­ÇغÎÇб³½Ç

Abstract

ħºÐºñÀúÇÏ, ±¸°­°ÇÁ¶Áõ ¹× ħ ¼ººÐÀÇ º¯È­¸¦ Æ÷ÇÔÇÑ ºñÁ¤»óÀûÀΠħºÐºñ´Â Ç׿ì¿ïÁ¦º¹¿ë°ú °ü·ÃµÈ Áß¿äÇÑ ºÎÀÛ¿ëÀÌ´Ù. ¼±ÅÃÀû ¼¼·ÎÅä´Ñ ÀçÈí¼ö ¾ïÁ¦Á¦(SSRI) Ç׿ì¿ïÁ¦ ¶ÇÇÑ ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀ» °¡Áö°í ÀÖ´Ù. ÇÏÁö¸¸ SSRI¿¡ ÀÇ ÇÑ Ä§ºÐºñÀúÇÏ ±â Àü°ú Ç×Äݸ°¼º ÀÛ¿ëÀº ¿ÏÀüÈ÷ ¹àÇôÁöÁö ¾Ê¾Ò´Ù. º» ¿¬±¸¿¡¼­´Â fluoxetineÀÇ ¸¸¼º Åõ¿© ÈÄ ÁãÀÇ Ä§»ù¿¡¼­ ħºÐºñ¿Í Äݸ°¼º ½ÅÈ£ ´Ü¹éÁú ¼öÄ¡ÀÇ º¯È­¸¦ È®ÀÎÇÏ¿´´Ù. µ¿¹°Àº Á¤»ó±º, Àú ³óµµ°æ±¸Åõ¿©±º (20 mg/kg p.o.), °í³óµµ°æ±¸Åõ¿©±º (40 mg/kg p.o.), Àú ³óµµº¹°­Åõ¿©±º (20 mg/kg i.p.) ±×¸®°í °í³óµµº¹°­Åõ¿©±º(40 mg/kg i.p.)À¸·Î ±¸ºÐÇÏ¿´´Ù. 4ÁÖ µ¿¾È fluoxetine Åõ¿© ÈÄ, ħÀ» ¼öÁýÇÏ¿© ħºÐºñ·®À» ÃøÁ¤ÇÏ¿´´Ù. ÈÄ¿¡ ħ»ù Á¶Á÷À» ÀûÃâÇÏ¿© muscrinic acetylcholine receptor M3 (mAchR M3)¿Í aquaporin5 (AQP5) Ç×ü¸¦ ÀÌ¿ëÇÏ¿© ´Ü¹éÁú Á¤·®À» ÇÏ¿´´Ù. ±× °á°ú º¹°­Åõ¿©±º¿¡¼­ ħ ºÐºñ·®ÀÇ °¨¼Ò°¡ ³ªÅ¸³µÁö¸¸, °æ±¸Åõ¿©±º¿¡¼­´Â ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù. ÀÌ °¨¼Ò ÆÐÅÏÀº mAchR M3 ¿Í AQP5 ´Ü¹éÁú ¼öÄ¡¿¡¼­µµ À¯»çÇÏ°Ô ³ªÅ¸³µ´Ù. ÀÌ·¯ÇÑ °á°ú´Â fluoxetine¿¡ ÀÇÇÑ Ä§ºÐºñÀúÇÏ°¡ Ç×Äݸ°¼º ÀÛ¿ë°ú °ü·ÃÀÌ ÀÖÀ½À» ½Ã»çÇÑ´Ù.

Abnormal salivation including hyposalivation, xerostomia, and changes in saliva composition is important side effect related to taking antidepressants. Selective serotonin re-uptake inhibitor (SSRI) antidepressants have also these side effects. However, hyposalivation mechanism and anticholinergic action by SSRis is not fully understood. In this study, we have examined changes in salivation and cholinergic signal proteins levels in the salivary gland of the rat after chronic fluoxetine administration. Animals were divided in to 5 groups with the control, lowdose p.o. (20 mg/kg p.o.), highdose p.o. (40 mg/kg p.o.), lowdose i.p. (20 mg/kg i.p.) and highdose i.p. (40 mg/kg i.p.) groups. After fluoxetine administration for 4 weeks, saliva collection began to determine the salivary flow rate. Next, salivary glands were removed, the salivary tissues processes for Western blot analysis (for muscrinci acetylcholine receptor M3 (mAchR M3) and aquaporin5 (AQP5)). The salivary flow rate was decreased with fluoxetine dose in the i.p. groups, but not in the p.o. groups. This decreasing pattern was similar to mAchR M3 and AQP5 protein level. These finding suggest that the hyposalivation by fluoxetine may related anticholinergic action.

Å°¿öµå

Ç׿ì¿ïÁ¦; ¼±ÅÃÀû ¼¼·ÎÅä´Ñ ÀçÈí¼ö ¾ïÁ¦Á¦; Ç÷ç¿Á¼¼Æ¾; ħºÐºñÀúÇÏ; ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü
Antidepressant; SSRI; Fluoxetine; Hyposalivation; Muscarinic acetyl choline receptor

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI